Trial Profile
Phase 1, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study of Subcutaneous APL-9 in Healthy Volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs APL 9 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions
- 02 Jul 2018 Status changed from not yet recruiting to discontinued.
- 01 Jul 2016 New trial record